Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E14.51 EPS (ttm)4.54 Insider Own0.40% Shs Outstand1.28B Perf Week2.63%
Market Cap84.04B Forward P/E9.51 EPS next Y6.93 Insider Trans-2.06% Shs Float1.26B Perf Month4.62%
Income5.90B PEG4.58 EPS next Q1.71 Inst Own82.10% Short Float1.06% Perf Quarter-1.35%
Sales22.32B P/S3.77 EPS this Y-45.60% Inst Trans-0.78% Short Ratio1.92 Perf Half Y-6.65%
Book/sh17.20 P/B3.83 EPS next Y1.17% ROA9.20% Target Price80.51 Perf Year-2.57%
Cash/sh21.87 P/C3.01 EPS next 5Y3.17% ROE26.80% 52W Range60.32 - 79.61 Perf YTD5.29%
Dividend2.52 P/FCF23.41 EPS past 5Y18.10% ROI12.00% 52W High-17.27% Beta1.14
Dividend %3.83% Quick Ratio3.50 Sales past 5Y14.60% Gross Margin78.50% 52W Low9.18% ATR1.55
Employees11000 Current Ratio3.60 Sales Q/Q3.80% Oper. Margin37.10% RSI (14)53.00 Volatility1.97% 2.23%
OptionableYes Debt/Eq1.21 EPS Q/Q32.10% Profit Margin26.40% Rel Volume0.63 Prev Close66.36
ShortableYes LT Debt/Eq1.10 EarningsMay 02 AMC Payout51.20% Avg Volume7.02M Price65.86
Recom2.20 SMA201.10% SMA501.09% SMA200-4.80% Volume4,441,934 Change-0.75%
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
May-20-19 10:18AM  A Look At The Fair Value Of Gilead Sciences, Inc. (NASDAQ:GILD) Simply Wall St.
May-19-19 02:00PM  Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
09:00AM  Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences Motley Fool
May-17-19 12:29PM  Who Had the Better Quarter: Gilead Sciences or Amgen? Motley Fool
May-16-19 02:49PM  A Leading HIV Drug Is Way Overpriced in the U.S. Bloomberg
10:49AM  Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study Zacks
06:00AM  Gilead- A Top Biotech for Turnaround Investors MoneyShow
May-15-19 05:37PM  Influential Women 2019: Top CFO Robin Washington pushes beyond her comfort zone American City Business Journals
05:00PM  Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019 Business Wire
11:07AM  Mallinckrodt Ends Enrollment in Phase III for Terlipressin Zacks
10:49AM  Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates Zacks
May-14-19 06:11PM  Lawsuit accuses Gilead of propping up cost of lifesaving HIV treatments by blocking generic competition CNBC
May-13-19 09:30AM  GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks
07:00AM  Market Morning: Kudlow Cracks, Brexiters Rage, Gilead Butters Up FDA, Philip Morris Backtracks Market Exclusive
May-12-19 09:01AM  Is It Finally Time to Buy Gilead Sciences? Motley Fool
May-10-19 03:27PM  Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1 Zacks
02:54PM  Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss Zacks
10:51AM  PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y Zacks
08:34AM  Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues Zacks
07:56AM  Drugmaker Gilead reaches multiyear agreement with White House to donate HIV prevention med CNBC
May-09-19 07:24PM  Gilead to donate HIV medication for up to 200,000 Americans a year MarketWatch
07:12PM  Drugmaker will donate meds for US push to end HIV epidemic Associated Press
06:17PM  Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates Zacks
05:11PM  Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic Business Wire
03:21PM  Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1 Zacks
02:33PM  Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks
02:00PM  Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat Zacks
09:30AM  Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year? Zacks
May-08-19 05:39PM  'The people that most need this drug can't afford it': HIV advocates target Gilead meeting, but company says they're wrong American City Business Journals
02:12PM  Gilead To Invest $109M In Goldfinch Bio For Kidney Drug Collaboration Benzinga
11:30AM  Edited Transcript of GILD earnings conference call or presentation 2-May-19 8:30pm GMT Thomson Reuters StreetEvents
08:34AM  Gilead strikes deal with biotech Goldfinch Bio to tackle kidney diseases MarketWatch
07:00AM  Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease Business Wire
06:24AM  Model N (MODN) Q2 2019 Earnings Call Transcript Motley Fool
May-07-19 04:57PM  Biotech ETFs in Focus on String of Q1 Earnings Beats Zacks
09:00AM  Where Will Gilead Sciences Spend Its Cash? Motley Fool
May-06-19 04:01PM  Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14 Business Wire
May-05-19 09:15AM  5 Things You Can Expect for Gilead Sciences With Its New CEO at the Helm Motley Fool
May-03-19 04:32PM  Is Gilead Stock Seeing The Light Of O'Day? HIV Drugs Bolster Views Investor's Business Daily
12:58PM  Gilead Sciences Rises on 1st-Quarter Results GuruFocus.com
12:32PM  Stocks making the biggest moves midday: Activision Blizzard, Dish Network, Tesla & more CNBC
11:37AM  Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates Zacks
10:45AM  Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1 Zacks
08:36AM  Gilead Sciences Has Right Prescription on First-Quarter Earnings TheStreet.com
08:00AM  Has Gilead Sciences Turned the Corner? Motley Fool
07:49AM  The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen Benzinga
06:30AM  Gilead Sciences Is Regaining Its Shine TheStreet.com
06:00AM  Gilead Sciences Returns to Growth in the First Quarter Motley Fool
12:03AM  Gilead Sciences Inc (GILD) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 06:02PM  Gilead to separate Kite cell therapy unit, posts higher profit Reuters
05:30PM  Gilead Stock Is Among The Biggest Biotech Stocks But Should You Buy It? Investor's Business Daily
05:28PM  Is Gilead's Former Golden Goose Stabilizing? Here's What Earnings Say Investor's Business Daily
05:26PM  Stocks making the biggest moves after hours: Shake Shack, CBS, Expedia and more CNBC
05:15PM  Gilead Sciences (GILD) Q1 Earnings Top Estimates Zacks
04:24PM  Gilead posts higher first-quarter profit; drug sales in line with expectations Reuters
04:21PM  Gilead Stock Is Up Because an Earnings Beat Is Welcome News Barrons.com
04:10PM  Gilead stock ticks higher as earnings beat Street, revenue doesn't MarketWatch
04:02PM  Gilead Sciences Announces Second Quarter 2019 Dividend Business Wire
04:01PM  Gilead Sciences Announces First Quarter 2019 Financial Results Business Wire
03:43PM  Genfit, Cymbay Hope to Crack Large Liver Disease Market GuruFocus.com
10:00AM  Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
06:00AM  Gilead Sciences Reports Earnings Today. Heres What to Expect. Barrons.com
05:11AM  Gilead tops earnings forecast as cancer drug drives sales Financial Times
01:50AM  Top 5 Things to Know in The Market on Thursday Investing.com
May-01-19 11:00PM  The start-up striving to accelerate drug discovery Financial Times
06:30PM  Gilead Sciences Expected to Earn $1.61 a Share TheStreet.com
06:07PM  Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings? Zacks
04:09PM  Gileads CFO to step down early next year American City Business Journals
09:28AM  What's in the Cards for Novavax (NVAX) This Earnings Season? Zacks
08:15AM  3 Things You Can Expect in Gilead Sciences' Q1 Earnings Update Motley Fool
07:39AM  The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue Benzinga
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
05:36PM  Eric Schmidt and Diane Greene to exit Alphabet board MarketWatch
05:34PM  Gilead's CFO, appointed to Google parent's board, to retire MarketWatch
05:23PM  Former Google execs Eric Schmidt, Diane Greene to leave board Reuters
04:27PM  Gilead Sciences Chief Financial Officer Robin Washington to Step Down in Early 2020 Business Wire
11:39AM  AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up? Zacks
10:10AM  Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y Zacks
10:02AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
09:49AM  Does Gilead Sciences, Inc.'s (NASDAQ:GILD) Debt Level Pose A Problem? Simply Wall St.
08:32AM  What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings? Zacks
08:16AM  What's in the Cards for Bausch Health (BHC) Q1 Earnings? Zacks
06:47AM  Will Gilead Stock Get A Needed Boost From This Weeks Earnings Report? InvestorPlace
Apr-29-19 06:14PM  Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings? Zacks
01:42PM  Beaten-down health-care companies join Apple and Google in earnings parade MarketWatch
08:25AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
Apr-28-19 11:52PM  Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock? Zacks
Apr-27-19 08:16AM  2 Reasons Gilead Sciences' NASH Program Could Bounce Back Motley Fool
07:33AM  How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life Motley Fool
Apr-26-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
04:07PM  Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings? Zacks
02:01PM  Is a Beat in Store for Glaxo (GSK) This Earnings Season? Zacks
Apr-25-19 04:09PM  Gilead Reverses After Liver-Disease Treatment Fails Its Second Key Test Investor's Business Daily
02:55PM  The Top 10 Biotechnology Companies (JNJ, ROG.VX) Investopedia
12:13PM  Gilead experimental NASH drug fails another study Reuters
10:34AM  Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth Zacks
10:13AM  Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment Benzinga
09:30AM  GILD vs. ALKS: Which Stock Is the Better Value Option? Zacks
08:47AM  Gilead shares slip 0.2% after second NASH trial fails MarketWatch
08:00AM  Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH) Business Wire
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM